Show simple item record

dc.contributor.authorBerenguer, Juan
dc.contributor.authorJarrín, Inmaculada
dc.contributor.authorPérez-Latorre, Leire
dc.contributor.authorHontañón, Víctor
dc.contributor.authorVivancos, María J.
dc.contributor.authorNavarro, Jordi
dc.contributor.authorTéllez, María J.
dc.contributor.authorGuardiola Tey, Josep Maria
dc.contributor.authorIribarren, José A.
dc.contributor.authorRivero-Juárez, Antonio
dc.contributor.authorMárquez, Manuel
dc.contributor.authorArtero, Arturo
dc.contributor.authorMorano, Luis
dc.contributor.authorSantos, Ignacio
dc.contributor.authorMoreno, Javier
dc.contributor.authorFariñas, María C.
dc.contributor.authorGalindo, María J.
dc.contributor.authorHernando, María A.
dc.contributor.authorMontero, Marta
dc.contributor.authorCifuentes, Carmen
dc.contributor.authorDomingo, Pere
dc.contributor.authorSanz, José
dc.contributor.authorDomíngez, Lourdes
dc.contributor.authorFerrero, Oscar L.
dc.contributor.authorDe la Fuente, Belén
dc.contributor.authorRodríguez, Carmen
dc.contributor.authorReus, Sergio
dc.contributor.authorHernández-Quero, José
dc.contributor.authorGaspar, Gabriel
dc.contributor.authorPérez-Martínez, Laura
dc.contributor.authorGarcía, Coral
dc.contributor.authorForce, Lluis
dc.contributor.authorVeloso, Sergio
dc.contributor.authorLosa, Juan E.
dc.contributor.authorVilaró, Josep
dc.contributor.authorBernal, Enrique
dc.contributor.authorArponen, Sari
dc.contributor.authorOrtí, Amat J.
dc.contributor.authorChocarro, Ángel
dc.contributor.authorTeira, Ramón
dc.contributor.authorAlonso, Gerardo
dc.contributor.authorSilvariño, Rafael
dc.contributor.authorVegas, Ana
dc.contributor.authorGeijo, Paloma
dc.contributor.authorBisbe, Josep
dc.contributor.authorEsteban, Herminia
dc.contributor.authorGonzález-García, Juan
dc.contributor.authorGeSIDA 8514 Study Group
dc.date.accessioned2021-06-17T15:45:16Z
dc.date.available2021-06-17T15:45:16Z
dc.date.issued2018-01
dc.identifier.citationBerenguer, Juan; Jarrín, Inmaculada; Pérez-Latorre, Leire [et al.]. Human immunodeficiency virus/hepatits C virus coinfection in Spain: elimination Is feasible, but the burden of residual cirrhosis will be significant. Open Forum Infectious Diseases, 2018, 5(1), [p. 1-8]. Disponible en: <https://academic.oup.com/ofid/article/5/1/ofx258/4804300>. Fecha de acceso: 17 jun. 2021. DOI: 10.1093/ofid/ofx258ca
dc.identifier.issn2328-8957ca
dc.identifier.urihttp://hdl.handle.net/20.500.12328/2635
dc.description.abstractBackground: We assessed the prevalence of antibodies against hepatitis C virus (HCV-Abs) and active HCV infection in patients infected with human immunodeficiency virus (HIV) in Spain in 2016 and compared the results with those of similar studies performed in 2002, 2009, and 2015. Methods: The study was performed in 43 centers during October–November 2016. The sample was estimated for an accuracy of 2% and selected by proportional allocation and simple random sampling. During 2016, criteria for therapy based on direct-acting antiviral agents (DAA) were at least significant liver fibrosis, severe extrahepatic manifestations of HCV, and high risk of HCV transmissibility. Results: The reference population and the sample size were 38904 and 1588 patients, respectively. The prevalence of HCV-Abs in 2002, 2009, 2015, and 2016 was 60.8%, 50.2%, 37.7%, and 34.6%, respectively (P trend <.001, from 2002 to 2015). The prevalence of active HCV in 2002, 2009, 2015, and 2016 was 54.0%, 34.0%, 22.1%, and 11.7%, respectively (P trend <.001). The anti-HCV treatment uptake in 2002, 2009, 2015, and 2016 was 23.0%, 48.0%, 59.3%, and 74.7%, respectively (P trend <.001). In 2016, HCV-related cirrhosis was present in 7.6% of all HIV-infected individuals, 15.0% of patients with active HCV, and 31.5% of patients who cleared HCV after anti-HCV therapy. Conclusions: Our findings suggest that with universal access to DAA-based therapy and continued efforts in prevention and screening, it will be possible to eliminate active HCV among HIV-infected individuals in Spain in the short term. However, the burden of HCV-related cirrhosis will continue to be significant among HIV-infected individuals.en
dc.format.extent8ca
dc.language.isoengca
dc.publisherInfectious Diseases Society of Americaca
dc.relation.ispartofOpen Forum Infectious Diseasesca
dc.relation.ispartofseries5;1
dc.rights© The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.comDOI: 10.1093/ofid/ofx258ca
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.otherCoinfeccióca
dc.subject.otherEpidemiologiaca
dc.subject.otherHepatitis Cca
dc.subject.otherTeràpia farmacològicaca
dc.subject.otherInfecció pel VIHca
dc.subject.otherCoinfecciónes
dc.subject.otherEpidemiologíaes
dc.subject.otherHepatitis Ces
dc.subject.otherTerapia farmacológicaes
dc.subject.otherInfección por VIHes
dc.subject.otherCoinfectionen
dc.subject.otherEpidemiologyen
dc.subject.otherHepatitis Cen
dc.subject.otherPharmacological therapyen
dc.subject.otherHIV infectionen
dc.titleHuman immunodeficiency virus/hepatits C virus coinfection in Spain: elimination Is feasible, but the burden of residual cirrhosis will be significanten
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc61ca
dc.subject.udc616.9ca
dc.identifier.doihttps://dx.doi.org/10.1093/ofid/ofx258ca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

© The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.comDOI: 10.1093/ofid/ofx258
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/4.0/